| Name | Title | Contact Details |
|---|
CirclePoint is a San Francisco, CA-based company in the Business Services sector.
Fountainhead Production is a Simsbury, CT-based company in the Business Services sector.
At Tronic, we believe blockchain technology is the solution to creating a thriving customer loyalty program and an entirely new brand experience. We work with forward thinking brands to electrify customer experiences with cutting-edge Web3-based loyalty solutions that drive engagement throughout the entire customer journey. Our platform creates streamlined customer experiences and gives companies a full picture of customer behavior, unlocking the door to hyper-personalized offers that provide real value and inspire loyalty. Tronic helps brands integrate blockchain and digital wallet capabilities in order to facilitate gamified rewards and loyalty benefits through all phases of the customer lifecycle. Our platform provides unprecedented data insights while keeping the consumer in control of their own data. We offer the perfect solution for brands that want to forge closer bonds with their communities and enhance their customer network. By leveraging 100+ years of combined experience helping Fortune 1000 companies rapidly scale, we are poised to maximize brand revenue opportunities, build devoted communities, and turn customers into loyalists. Tronic goes beyond the boundaries of traditional loyalty programs. Will you join us?
Southeast Produce Council is a Riverview, FL-based company in the Business Services sector.
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.